Todd Franklin Watanabe
Net Worth
Last updated:
What is Todd Franklin Watanabe net worth?
The estimated net worth of Mr. Todd Franklin Watanabe is at least $18,847,410 as of 20 Dec 2024. He owns shares worth $12,825,746 as insider, has earned $2,348,514 from insider trading and has received compensation worth at least $3,673,150 in Arcutis Biotherapeutics, Inc..
What is the salary of Todd Franklin Watanabe?
Mr. Todd Franklin Watanabe salary is $734,630 per year as Pres, Chief Executive Officer & Director in Arcutis Biotherapeutics, Inc..
How old is Todd Franklin Watanabe?
Mr. Todd Franklin Watanabe is 57 years old, born in 1968.
What stocks does Todd Franklin Watanabe currently own?
As insider, Mr. Todd Franklin Watanabe owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Arcutis Biotherapeutics, Inc. (ARQT) | Pres, Chief Executive Officer & Director | 823,430 | $15.58 | $12,825,746 |
What does Arcutis Biotherapeutics, Inc. do?
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Todd Franklin Watanabe insider trading
Arcutis Biotherapeutics, Inc.
Mr. Todd Franklin Watanabe has made 53 insider trades between 2020-2024, according to the Form 4 filled with the SEC. Most recently he sold 15,000 units of ARQT stock worth $227,565 on 20 Dec 2024.
The largest trade he's ever made was exercising 59,525 units of ARQT stock on 1 Dec 2023. As of 20 Dec 2024 he still owns at least 823,430 units of ARQT stock.
Arcutis Biotherapeutics key executives
Arcutis Biotherapeutics, Inc. executives and other stock owners filed with the SEC:
- Dr. Bhaskar Chaudhuri Ph.D. (70) Co-Founder & Independent Director
- Dr. Patrick E. Burnett M.D., Ph.D. (53) Senior Vice President & Chief Medical Officer
- Mr. Kenneth A. Lock (51) Chief Commercial Officer
- Mr. Todd Franklin Watanabe (57) Pres, Chief Executive Officer & Director